<DOC>
	<DOC>NCT01598051</DOC>
	<brief_summary>The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice. A total of 725 patients are to be enrolled and followed for a 6 months.period. QOL survey will be conducted at month 0, 3, 6 using ACTS/TSQM. This study is categorized as a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.</brief_summary>
	<brief_title>Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients treated by Warfarin for their atrial fibrillation for at least two months at the time of the study initiation. Rivaroxaban na√Øve patients Patients 20 years old or older. Patients who agree to sign the inform consent Patients who are contraindicated by product label</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Xarelto</keyword>
	<keyword>SPAF</keyword>
	<keyword>QOL</keyword>
</DOC>